Welcome to the Men's Health Knowledge Centre
As a disease topic Men's Health covers a broad set of issues affecting men of all ages. Some of the issues requiring greater focus and more thorough dissemination of information amongst the healthcare community, are those that have the potential to go undetected in the early stages. These include, hypogonadism and erectile dysfunction.
Early detection and more regular health checks of these diseases, not only improve prognosis and efficacy of treatment outcomes, but also quality of life.
- June 2014 - Testosterone and Prostate Cancer - a paradigm shift
"Bye-bye Androgen Hypothesis, Welcome Saturation Model"
- The "saturation model" explains the paradoxical observations that prostate tissue is extremely sensitive to changes in testosterone at low concentrations but becomes indifferent to changes at higher testosterone concentrations.
- A threshold effect occurs in which increasing androgen concentrations reach a limit (the saturation point) beyond which there is no further ability to induce androgen-driven changes in prostate tissue growth.
- A mechanism contributing to the saturation model is the finite ability of androgens to bind to the androgen receptor (AR). Maximal androgen-AR binding (i.e., saturation) occurs at fairly low androgen levels. It has been established in clinical practice that the saturation point appears to be around 8 nmol/L (230 ng/dL), subject to inter-individual variation.
- The current ISA, ISSAM, EAU, EAA, ASA guidelines state:
- There is no conclusive evidence that testosterone therapy increases the risk of prostate cancer or benign prostatic hyperplasia.
- There is also no evidence that testosterone treatment will convert subclinical prostate cancer to clinically detectable prostate cancer.
- Provocative new research evidence suggests that it is not high serum T that is problematic for PCa, but to the contrary that it is low serum T that is associated with worrisome prostate cancer features and outcomes.